ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2013
Nutraceuticals safety and efficacy in migraine without aura in a population of children affected by neurofibromatosis type I.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Systematic Review Suggests Nutraceuticals Containing Vitamin B2 Could Provide an Alternative Treatment for Paediatric Migraines.Acta paediatrica (Oslo, Norway : 1992) · 2025Pooled it
- Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine-a meta-analysis.BMJ open · 2021Pooled it
- Effects of Jianpi Qingchang decoction on the quality of life of patients with ulcerative colitis: A randomized controlled trial.Medicine · 2017Trial
- Polysomnographic study in pediatric neurofibromatosis type 1.Frontiers in neurology · 2023Article
- Managing Headache Disorders Associated with Tuberous Sclerosis and Neurofibromatosis.Current pain and headache reports · 2022Review
- Review
- Article
- The Rorschach Test Evaluation in Chronic Childhood Migraine: A Preliminary Multicenter Case-Control Study.Frontiers in neurology · 2017Article
- Visual-spatial training efficacy in children affected by migraine without aura: a multicenter study.Neuropsychiatric disease and treatment · 2017Article
- Treatment of neurofibromatosis type 1.Current treatment options in neurology · 2015Article
- Microemulsion of babassu oil as a natural product to improve human immune system function.Drug design, development and therapy · 2015Article
- Neurofibromatosis type 1 and attention deficit hyperactivity disorder: a case study and literature review.Neuropsychiatric disease and treatment · 2015Article
- Anxiety and depression levels in prepubertal obese children: a case-control study.Neuropsychiatric disease and treatment · 2014Article
- Phyllostachys edulis extract induces apoptosis signaling in osteosarcoma cells, associated with AMPK activation.Drug design, development and therapy · 2014Article
- Decreased mean platelet volume in panic disorder.Neuropsychiatric disease and treatment · 2014Article
- Generation of superoxide anion radicals and platelet glutathione peroxidase activity in patients with schizophrenia.Neuropsychiatric disease and treatment · 2014Article
- Orthodontic treatment need for adolescents in the Campania region: the malocclusion impact on self-concept.Patient preference and adherence · 2014Article
- Pediatric neurofibromatosis 1 and parental stress: a multicenter study.Neuropsychiatric disease and treatment · 2014Article
- Self-concept evaluation and migraine without aura in childhood.Neuropsychiatric disease and treatment · 2013Article
- Temperamental characteristics in childhood migraine without aura: a multicenter study.Neuropsychiatric disease and treatment · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurofibromatosis type 1 (NF1) is one of the most common autosomal dominant disorders with a prevalence of one in 4,000 people worldwide, associated with many neurological comorbidities, such as headache. Despite the high prevalence of headache in this population, little data exist regarding the classification of headaches experienced by patients with NF1. Aim of this study is to verify the efficacy and safety of a nutraceutical complex containing Ginkgolide B/Coenzyme Q10/Riboflavin/Magnesium for prophylaxis in a sample of children affected by NF1 presenting migraine without aura. Ginkgolide B/Coenzyme Q10/Riboflavin/Magnesium complex was orally administered twice a day for 6 months, to 18 school-aged patients with NF1 and presenting symptoms of migraine without aura (10 M, mean age 8.4 ± 1.65). Each patient kept a journal to record: number, intensity (according VAS scale), duration of attacks and concomitant symptoms. In addition, the PedMIDAS scale was administered to assess migraine-related disability. To verify the efficacy of the association, we tested the starting frequency (T0) of headache after 6 months (T1) and then we calculated the migraine frequency delta percentage to express the decrease in monthly frequency. After treatment, a reduction was reported (p < 0.001) in all migraine outcomes (frequency, duration, intensity, and grade of disability). In conclusion, the present study should be considered as the first report on the efficacy and safety of nutraceutical complex containing Ginkgolide B/Coenzyme Q10/Riboflavin/Magnesium for the prophylaxis of migraine in children affected by NF1. Our findings suggest that headache symptoms should be considered a therapeutic target independent of primary disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.